ArticleEcancermedicalscience2020
Tumour-infiltrating Langerhans cells in non-melanoma skin cancer, a clinical and immunohistochemical study.
Article in Ecancermedicalscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Single-Cell Profiling Reveals Global Immune Responses During the Progression of Murine Epidermal Neoplasms.Cancers · 2025Article
- Assessing the Correlation Between Langerhans Cells Population and Prognosis of Tongue Squamous Cell Carcinoma.Clinical and experimental dental research · 2025Article
- The roles of tissue resident macrophages in health and cancer.Experimental hematology & oncology · 2024Review
- Langerhans Cells-Revising Their Role in Skin Pathologies.Journal of personalized medicine · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-melanoma skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) represents 78.5% of all skin malignant tumours in Egypt. Dendritic cells can be found in almost all human tumours, they play an important role in antitumour immunity. The aim of the present study was to evaluate the percentage of Langerhans cells using CD1a in non-melanoma skin cancer, including BCC and SCC and to correlate this percentage with their clinicopathological features. The current study was performed on surgically excised specimens of 41 patients presented with non-melanoma skin cancer (26 BCC and 15 SCC) and 16 healthy volunteer control subjects. The mean and median percentage of Langerhans cells were higher in normal epidermis of control compared to malignant tumour tissue (p < 0.0001) and adjacent epidermis overlying malignant tumour tissue (p = 0.007). Langerhans cells were significantly seen in BCC cases more than SCC (p = 0.035) and they were seen in facial lesions more than those arising from other sites (p = 0.007). The reduction of Langerhans cells is a way for non-melanoma skin cancer to develop and progress. Marked reduction of Langerhans cells in SCC compared to BCC could refer to their role as a barrier against metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.